Your core team consists of the following members. In addition, we have an extensive network of associates with domain-specific experiences.
Katherine Tynan Ph.D.
Katherine is a seasoned biotechnology entrepreneur with a focus on business development, startup entrepreneurship, fundraising and strategic business planning for clinical diagnostic companies and investors. She has a breadth of experience in development and commercialization of new technologies for clinical diagnostics including diagnostic reimbursement, financial analysis, operations, and product development. Katherine has served on and continues to work closely with the economic advisory committee for the Association of Molecular Pathology (AMP). She is actively sought after to speak and moderate sessions at industry meetings on the topics of reimbursement, new technologies and commercial challenges for emerging diagnostic tests.
As a consultant, Katherine has worked with a number of early stage and established diagnostic companies guiding them through product development choices, market entry strategies, funding ($21M raised) and a diverse range of business development transactions.
Prior to consulting, Katherine was at Vitra Bioscience (VP of Strategic Marketing), a venture-backed biotechnology tools company, where she managed a broad range of functional areas including marketing, business development, operations, finance, legal, IP and participated in raising over $15M in capital. Previously, Katherine worked at Applied Biosystems in strategic planning (including Celera and Celera Diagnostics), business development, research management and product development roles. Prior to Applied Biosystems, Katherine directed the Molecular Genetics Department for Oncogenetics / Datagenetics, a start-up esoteric diagnostic services company (acquired by Impath and subsequently by Genzyme). Katherine also conducted post-doctoral studies on Marfan Syndrome at Stanford University and in conjunction with the Human Genome Project at Lawrence Livermore National Laboratory. She was board certified by the American College of Medical Genetics (ACMG) in Clinical Molecular Genetics from 1993 through 2003. Katherine holds a Ph.D. in Human Genetics from the University of Calgary, Canada and a B.S. (Hons) in Microbiology from University College Galway, Ireland.
Paul Cannon Ph.D.
Paul is an executive with over 15 years experience in pharmaceutical research and development. Before joining Tynan Consulting, Paul was Head of Operations for the Inflammation Disease Biology Area at Roche. In this role, he was a key member of the leadership team for Inflammation Research and early development providing scientific, strategic and operational oversight of a budget in excess of $40M. Prior to this he held a number of positions of strategic and operational importance at both Syntex and Roche. These included Head of Research, Project and Portfolio Management for Roche Bioscience; Vice President and Head of CNS Discovery for Roche Palo Alto (30 FTE R&D team); and Head of the Core sciences group for the Neurobiology business unit. Paul has extensive experience in drug discovery in CNS, Inflammation and Musculoskeletal disease areas as well as a strong background in new technology evaluation and implementation.
Paul also conducted post-doctoral training with Gordon Ringold at Syntex Pharmaceuticals. Paul received a first class honors B.A. degree in Natural Sciences from the University of Cambridge in the UK, and a Ph.D. in Medical Sciences from the University of Calgary, Alberta, Canada.